| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tissue and Organ Procurement | 8 | 2021 | 43 | 3.460 |
Why?
|
| Waiting Lists | 9 | 2021 | 36 | 2.640 |
Why?
|
| Registries | 8 | 2020 | 335 | 2.240 |
Why?
|
| Lung Transplantation | 3 | 2018 | 20 | 1.890 |
Why?
|
| Heart Transplantation | 3 | 2018 | 42 | 1.890 |
Why?
|
| Kidney Transplantation | 3 | 2018 | 86 | 1.760 |
Why?
|
| Liver Transplantation | 4 | 2021 | 30 | 1.730 |
Why?
|
| Tissue Donors | 4 | 2018 | 44 | 1.500 |
Why?
|
| Graft Survival | 4 | 2020 | 39 | 1.350 |
Why?
|
| Graft Rejection | 2 | 2018 | 38 | 1.280 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 404 | 1.060 |
Why?
|
| Models, Statistical | 2 | 2015 | 180 | 0.880 |
Why?
|
| Postoperative Complications | 4 | 2020 | 210 | 0.800 |
Why?
|
| Survival Rate | 3 | 2018 | 311 | 0.800 |
Why?
|
| Resource Allocation | 2 | 2018 | 11 | 0.800 |
Why?
|
| Computer Simulation | 5 | 2016 | 362 | 0.790 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2018 | 42 | 0.740 |
Why?
|
| Transplants | 2 | 2018 | 2 | 0.700 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 145 | 0.680 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 190 | 0.660 |
Why?
|
| Donor Selection | 2 | 2017 | 7 | 0.650 |
Why?
|
| Organ Transplantation | 4 | 2020 | 18 | 0.650 |
Why?
|
| Transplantation | 1 | 2018 | 2 | 0.630 |
Why?
|
| Health Care Rationing | 1 | 2018 | 5 | 0.630 |
Why?
|
| Decision Making | 2 | 2017 | 203 | 0.610 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2017 | 2 | 0.600 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 9 | 0.590 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 56 | 0.590 |
Why?
|
| Prognosis | 6 | 2018 | 739 | 0.590 |
Why?
|
| Humans | 42 | 2021 | 37093 | 0.580 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 268 | 0.530 |
Why?
|
| Cultural Diversity | 1 | 2016 | 169 | 0.520 |
Why?
|
| Games, Experimental | 1 | 2014 | 3 | 0.500 |
Why?
|
| Competency-Based Education | 1 | 2014 | 10 | 0.500 |
Why?
|
| Bioterrorism | 1 | 2014 | 20 | 0.490 |
Why?
|
| Education, Public Health Professional | 1 | 2014 | 19 | 0.490 |
Why?
|
| Civil Defense | 1 | 2014 | 11 | 0.490 |
Why?
|
| Survival Analysis | 1 | 2015 | 325 | 0.470 |
Why?
|
| Female | 29 | 2020 | 20969 | 0.460 |
Why?
|
| Follow-Up Studies | 5 | 2018 | 974 | 0.450 |
Why?
|
| Health Status Disparities | 2 | 2016 | 642 | 0.450 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2014 | 14 | 0.430 |
Why?
|
| Antibodies, Protozoan | 4 | 2017 | 79 | 0.420 |
Why?
|
| Regression Analysis | 1 | 2013 | 455 | 0.420 |
Why?
|
| Facial Asymmetry | 1 | 2011 | 1 | 0.410 |
Why?
|
| Malocclusion, Angle Class II | 1 | 2011 | 2 | 0.410 |
Why?
|
| Malocclusion, Angle Class I | 1 | 2011 | 5 | 0.410 |
Why?
|
| Male | 24 | 2020 | 20025 | 0.410 |
Why?
|
| Child | 12 | 2021 | 3131 | 0.360 |
Why?
|
| Middle Aged | 11 | 2020 | 10129 | 0.350 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 610 | 0.340 |
Why?
|
| Adult | 15 | 2020 | 11712 | 0.330 |
Why?
|
| Living Donors | 2 | 2018 | 15 | 0.320 |
Why?
|
| Cystic Fibrosis | 2 | 2018 | 18 | 0.310 |
Why?
|
| Antigens, Protozoan | 2 | 2015 | 72 | 0.260 |
Why?
|
| Adolescent | 11 | 2018 | 5363 | 0.250 |
Why?
|
| Program Evaluation | 2 | 2018 | 339 | 0.250 |
Why?
|
| Malaria, Falciparum | 2 | 2015 | 90 | 0.240 |
Why?
|
| Odontometry | 2 | 2014 | 2 | 0.240 |
Why?
|
| Technology, Dental | 2 | 2014 | 2 | 0.240 |
Why?
|
| Emergency Service, Hospital | 4 | 2018 | 208 | 0.230 |
Why?
|
| Statistics, Nonparametric | 2 | 2015 | 108 | 0.220 |
Why?
|
| Minnesota | 4 | 2018 | 40 | 0.220 |
Why?
|
| Risk Factors | 4 | 2020 | 3562 | 0.220 |
Why?
|
| Retrospective Studies | 9 | 2018 | 2026 | 0.210 |
Why?
|
| Young Adult | 9 | 2018 | 4268 | 0.210 |
Why?
|
| Aged | 6 | 2020 | 6741 | 0.190 |
Why?
|
| Child, Preschool | 7 | 2020 | 1418 | 0.180 |
Why?
|
| Time Factors | 4 | 2018 | 1742 | 0.180 |
Why?
|
| Liver Diseases | 1 | 2020 | 33 | 0.180 |
Why?
|
| Choice Behavior | 1 | 2020 | 79 | 0.170 |
Why?
|
| Dental Care | 1 | 2019 | 26 | 0.170 |
Why?
|
| Patient Advocacy | 1 | 2018 | 21 | 0.160 |
Why?
|
| Pseudomonas Infections | 1 | 2018 | 18 | 0.160 |
Why?
|
| Ondansetron | 1 | 2018 | 3 | 0.160 |
Why?
|
| Antiemetics | 1 | 2018 | 7 | 0.160 |
Why?
|
| Autistic Disorder | 3 | 2015 | 37 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 1 | 2018 | 61 | 0.160 |
Why?
|
| Dehydration | 1 | 2018 | 21 | 0.160 |
Why?
|
| Fluid Therapy | 1 | 2018 | 28 | 0.160 |
Why?
|
| Gastroenteritis | 1 | 2018 | 17 | 0.160 |
Why?
|
| Triage | 1 | 2018 | 26 | 0.160 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2018 | 57 | 0.160 |
Why?
|
| Appendicitis | 1 | 2018 | 17 | 0.150 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2017 | 5 | 0.150 |
Why?
|
| Gastrostomy | 1 | 2017 | 7 | 0.150 |
Why?
|
| Gastric Bypass | 1 | 2017 | 17 | 0.150 |
Why?
|
| Ultrasonography | 1 | 2018 | 112 | 0.150 |
Why?
|
| Drainage, Postural | 1 | 2017 | 1 | 0.150 |
Why?
|
| Chest Wall Oscillation | 1 | 2017 | 1 | 0.150 |
Why?
|
| Hospitalization | 2 | 2018 | 388 | 0.150 |
Why?
|
| Age Factors | 2 | 2018 | 1033 | 0.150 |
Why?
|
| Respiratory Therapy | 1 | 2017 | 3 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2017 | 753 | 0.150 |
Why?
|
| Laryngeal Masks | 1 | 2016 | 1 | 0.150 |
Why?
|
| Treatment Outcome | 2 | 2018 | 1369 | 0.140 |
Why?
|
| Intubation, Intratracheal | 1 | 2016 | 19 | 0.140 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2016 | 56 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 214 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 534 | 0.140 |
Why?
|
| Sulfadoxine | 1 | 2015 | 6 | 0.140 |
Why?
|
| Infant, Premature | 1 | 2016 | 129 | 0.140 |
Why?
|
| Pyrimethamine | 1 | 2015 | 10 | 0.140 |
Why?
|
| Infant | 5 | 2018 | 1046 | 0.130 |
Why?
|
| Antibody Affinity | 1 | 2015 | 25 | 0.130 |
Why?
|
| Plasmodium falciparum | 1 | 2017 | 135 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 198 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2017 | 212 | 0.130 |
Why?
|
| Monitoring, Intraoperative | 1 | 2015 | 3 | 0.130 |
Why?
|
| Aortic Coarctation | 1 | 2015 | 2 | 0.130 |
Why?
|
| Fetal Heart | 1 | 2015 | 4 | 0.130 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2015 | 2 | 0.130 |
Why?
|
| Mucopolysaccharidosis III | 1 | 2015 | 2 | 0.130 |
Why?
|
| Accidental Falls | 1 | 2015 | 26 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 251 | 0.130 |
Why?
|
| Antimalarials | 1 | 2015 | 55 | 0.130 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2015 | 20 | 0.130 |
Why?
|
| Rural Health | 1 | 2015 | 53 | 0.130 |
Why?
|
| Aorta, Thoracic | 1 | 2015 | 28 | 0.130 |
Why?
|
| Biostatistics | 1 | 2015 | 7 | 0.130 |
Why?
|
| Germany | 1 | 2015 | 24 | 0.130 |
Why?
|
| Fractures, Bone | 1 | 2015 | 53 | 0.130 |
Why?
|
| Behavior | 1 | 2015 | 32 | 0.130 |
Why?
|
| Receptor, erbB-2 | 1 | 2016 | 133 | 0.130 |
Why?
|
| Kidney | 1 | 2017 | 337 | 0.130 |
Why?
|
| Nonlinear Dynamics | 1 | 2015 | 33 | 0.130 |
Why?
|
| Nutrition Assessment | 1 | 2015 | 79 | 0.120 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 60 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 441 | 0.120 |
Why?
|
| Patient Satisfaction | 2 | 2012 | 145 | 0.120 |
Why?
|
| Models, Educational | 1 | 2014 | 44 | 0.120 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 1502 | 0.120 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2015 | 103 | 0.120 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 85 | 0.120 |
Why?
|
| Vegetables | 1 | 2015 | 147 | 0.120 |
Why?
|
| Educational Measurement | 1 | 2014 | 86 | 0.120 |
Why?
|
| Linear Models | 1 | 2015 | 275 | 0.120 |
Why?
|
| Hawaii | 2 | 2019 | 1929 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1039 | 0.120 |
Why?
|
| Cytomegalovirus Vaccines | 1 | 2013 | 1 | 0.120 |
Why?
|
| Penicillamine | 1 | 2013 | 3 | 0.120 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2013 | 4 | 0.120 |
Why?
|
| Prothrombin Time | 1 | 2013 | 10 | 0.120 |
Why?
|
| Fruit | 1 | 2015 | 173 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2015 | 291 | 0.120 |
Why?
|
| Disaster Planning | 1 | 2014 | 52 | 0.120 |
Why?
|
| Bilirubin | 1 | 2013 | 17 | 0.110 |
Why?
|
| Infant, Newborn | 4 | 2018 | 894 | 0.110 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 23 | 0.110 |
Why?
|
| Monte Carlo Method | 1 | 2013 | 57 | 0.110 |
Why?
|
| Vaccines, Attenuated | 1 | 2013 | 72 | 0.110 |
Why?
|
| Cytomegalovirus | 1 | 2013 | 40 | 0.110 |
Why?
|
| United States | 3 | 2018 | 4223 | 0.110 |
Why?
|
| Babesiosis | 1 | 2012 | 1 | 0.110 |
Why?
|
| Babesia microti | 1 | 2012 | 1 | 0.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2013 | 72 | 0.110 |
Why?
|
| Blood Donors | 1 | 2012 | 17 | 0.110 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2012 | 4 | 0.110 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1067 | 0.110 |
Why?
|
| Curriculum | 1 | 2014 | 265 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 2721 | 0.100 |
Why?
|
| Viral Proteins | 1 | 2013 | 174 | 0.100 |
Why?
|
| Cephalometry | 1 | 2011 | 23 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 63 | 0.100 |
Why?
|
| Motivation | 1 | 2014 | 436 | 0.090 |
Why?
|
| Students | 1 | 2015 | 519 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2011 | 550 | 0.090 |
Why?
|
| Pregnancy | 4 | 2015 | 1549 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2012 | 294 | 0.090 |
Why?
|
| Health Promotion | 1 | 2015 | 653 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2020 | 208 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2016 | 1908 | 0.070 |
Why?
|
| Cameroon | 2 | 2015 | 38 | 0.070 |
Why?
|
| Quality of Health Care | 2 | 2018 | 138 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 935 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 54 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2379 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 139 | 0.040 |
Why?
|
| Tobramycin | 1 | 2018 | 3 | 0.040 |
Why?
|
| Neonatal Screening | 1 | 2018 | 25 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2018 | 80 | 0.040 |
Why?
|
| Oral Health | 1 | 2019 | 68 | 0.040 |
Why?
|
| Geography | 1 | 2018 | 96 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2018 | 15 | 0.040 |
Why?
|
| Appendectomy | 1 | 2018 | 16 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2018 | 20 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 348 | 0.040 |
Why?
|
| Cadaver | 1 | 2017 | 42 | 0.040 |
Why?
|
| Monitoring, Ambulatory | 1 | 2017 | 13 | 0.040 |
Why?
|
| Outpatients | 1 | 2017 | 33 | 0.040 |
Why?
|
| Videotape Recording | 1 | 2016 | 23 | 0.040 |
Why?
|
| Length of Stay | 1 | 2018 | 185 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2017 | 70 | 0.040 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 94 | 0.040 |
Why?
|
| Placenta Diseases | 1 | 2015 | 5 | 0.030 |
Why?
|
| Insecticide-Treated Bednets | 1 | 2015 | 8 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 60 | 0.030 |
Why?
|
| Community Health Services | 1 | 2017 | 185 | 0.030 |
Why?
|
| Parity | 1 | 2015 | 46 | 0.030 |
Why?
|
| South Dakota | 1 | 2015 | 1 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 143 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2015 | 98 | 0.030 |
Why?
|
| Oxygen | 1 | 2016 | 207 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 352 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 2015 | 12 | 0.030 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2015 | 12 | 0.030 |
Why?
|
| Heart Rate | 1 | 2016 | 253 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2015 | 33 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2015 | 37 | 0.030 |
Why?
|
| Health Behavior | 1 | 2019 | 537 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 408 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 601 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 96 | 0.030 |
Why?
|
| Gestational Age | 1 | 2015 | 190 | 0.030 |
Why?
|
| Calcium Sulfate | 1 | 2014 | 1 | 0.030 |
Why?
|
| Jaw Relation Record | 1 | 2014 | 2 | 0.030 |
Why?
|
| Malocclusion | 1 | 2014 | 2 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 560 | 0.030 |
Why?
|
| Dental Materials | 1 | 2014 | 3 | 0.030 |
Why?
|
| Efficiency | 1 | 2014 | 16 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2014 | 22 | 0.030 |
Why?
|
| Tooth | 1 | 2014 | 12 | 0.030 |
Why?
|
| Amygdala | 1 | 2015 | 114 | 0.030 |
Why?
|
| Information Systems | 1 | 2014 | 15 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 52 | 0.030 |
Why?
|
| Lung | 1 | 2017 | 446 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2018 | 1378 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2014 | 62 | 0.030 |
Why?
|
| Gene Order | 1 | 2013 | 17 | 0.030 |
Why?
|
| Social Behavior | 1 | 2015 | 131 | 0.030 |
Why?
|
| Guinea Pigs | 1 | 2013 | 145 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2013 | 87 | 0.030 |
Why?
|
| Life Style | 1 | 2015 | 308 | 0.030 |
Why?
|
| Algorithms | 1 | 2016 | 465 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 84 | 0.030 |
Why?
|
| DNA, Protozoan | 1 | 2012 | 24 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2012 | 35 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2013 | 87 | 0.030 |
Why?
|
| Asperger Syndrome | 1 | 2012 | 1 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2012 | 68 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1130 | 0.030 |
Why?
|
| Disabled Children | 1 | 2012 | 9 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 922 | 0.030 |
Why?
|
| Seasons | 1 | 2012 | 112 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 689 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 885 | 0.030 |
Why?
|
| Fear | 1 | 2015 | 249 | 0.030 |
Why?
|
| Child Health Services | 1 | 2012 | 43 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 898 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2012 | 136 | 0.030 |
Why?
|
| Vaccination | 1 | 2013 | 288 | 0.020 |
Why?
|
| Virus Replication | 1 | 2013 | 278 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 146 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1198 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 1354 | 0.020 |
Why?
|
| Parents | 1 | 2012 | 329 | 0.020 |
Why?
|
| Animals | 1 | 2013 | 15081 | 0.010 |
Why?
|